Cost-of-illness of gastroenteritis caused by rotavirus in Chinese children less than 5 years

Hum Vaccin Immunother. 2023 Dec 15;19(3):2276619. doi: 10.1080/21645515.2023.2276619. Epub 2023 Nov 27.

Abstract

Acute gastroenteritis (AGE) caused by rotavirus (RV) remains a public health issue in China. To accelerate the mass rotavirus vaccination, it is important to inform the policy maker, and the public of the economic burden caused by rotavirus infection. A meta-analysis was conducted applying standardized algorithms. Articles published before January 1, 2023, in English and Chinese were searched through PubMed, CNKI, and WanFang Data. Studies with cost analysis of RV AGE were included. A random-effects model was applied to synthesize the total cost of RV AGE from the societal perspective. A prospective survey aimed to measure the cost of RV AGE was conducted in 2021 and 2022 in Shaoxing city, Zhejiang province, that can represent the developed region. The cost data was applied as deviation indicator, in comparison with the pooled estimate generated from meta-analysis. Totally 286 articles were identified, and eventually 12 studies were included. The pooled total social cost of RV AGE was US$282.1 (95%CI: US$213.4-350.7). The pooled private cost of RV AGE was US$206.4 (95%CI: US$155.2-257.5). RV AGE hospitalized and RV AGE incurred in developed regions caused remarkable higher burden (US$631.2 [95%CI: US$512.6-749.8], and US$333.6 [95%CI: US$234.1-433.2] respectively), compared to RV AGE treated at outpatient, and incurred in less developed regions. Our study demonstrates that RV AGE causes a significant economic burden in China. Given the promising effectiveness and highly cost-effective, introduction of rotavirus vaccines in national immunization programs could substantially reduce the economic burden in China.

Keywords: China; Rotavirus; acute gastroenteritis; economic burden.

Publication types

  • Meta-Analysis

MeSH terms

  • Child, Preschool
  • Cost-Benefit Analysis
  • East Asian People
  • Gastroenteritis* / epidemiology
  • Gastroenteritis* / prevention & control
  • Gastroenteritis* / virology
  • Humans
  • Infant
  • Mass Vaccination
  • Prospective Studies
  • Rotavirus
  • Rotavirus Infections* / epidemiology
  • Rotavirus Infections* / prevention & control
  • Rotavirus Vaccines*

Substances

  • Rotavirus Vaccines

Grants and funding

This work was funded by MSD R&D (CHINA) CO., LTD.